Clinical Trials Sponsored by Renovo

Total 1886 results

Novo Nordisk A/S

Completed

A Study to Look at How Safe NNC0268-0965 is in Healthy People and People With Type 1 Diabetes

Diabetes Mellitus, Type 1 | Healthy Volunteers

Germany
Novo Nordisk A/S

Completed

A Trial Investigating Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of a Single Dose of Long-acting Growth Hormone (Somapacitan) Compared to Daily Dosing of Norditropin® SimpleXx® in Children With Growth Hormone Deficiency

Growth Hormone Disorder | Growth Hormone Deficiency in Children

France, Israel, Austria, Spain, Switzerland, North Macedonia, Norway, Slovenia, Belgium, Sweden
Novo Nordisk A/S

Completed

First Human Dose Trial of NNC0195-0092 (Somapacitan) in Healthy Subjects

Healthy | Growth Hormone Disorder | Growth Hormone Deficiency in Children | Adult Growth Hormone Deficiency

Germany
Novo Nordisk A/S

Completed

Safety and Efficacy of Turoctocog Alfa in Prevention and Treatment of Bleeds in Previously Untreated Children With Haemophilia A (guardian™4)

Congenital Bleeding Disorder | Haemophilia A

United States, Denmark, Austria, Spain, Japan, Brazil, Algeria, Lithuania, Portugal, Russian Federation, Serbia, Turkey, Greece, Hong Kong, Puerto Rico, Hungary, China, Poland
Novo Nordisk A/S

Completed

A Multinational, Open-Label, Non-Controlled Trial on Safety, Efficacy and Pharmacokinetics of NNC 0129-0000-1003 in Previously Treated Paediatric Patients With Severe Haemophilia A (pathfinder™5)

Congenital Bleeding Disorder | Haemophilia A

France, United States, Switzerland, Malaysia, Brazil, Canada, Japan, United Kingdom, Israel, Portugal, Ukraine, Greece, Lithuania, Puerto Rico, Turkey, Italy
Novo Nordisk A/S

Completed

Trial to Compare the Efficacy and Safety of NNC0195-0092 (Somapacitan) With Placebo and Norditropin® FlexPro® (Somatropin) in Adults With Growth Hormone Deficiency. (REAL 1)

Growth Hormone Disorder | Adult Growth Hormone Deficiency

United States, Poland, India, Japan, Russian Federation, United Kingdom, Germany, Sweden, Israel, Malaysia, Turkey, South Africa, Australia, Latvia, Lithuania, Romania, Brazil, Norway, Ukraine
Novo Nordisk A/S

Completed

A Clinical Trial Comparing Glycaemic Control and Safety of Insulin Degludec/Liraglutide (IDegLira) Versus Insulin Glargine (IGlar) as add-on Therapy to SGLT2i in Subjects With Type 2 Diabetes Mellitus (DUALTM IX)

Diabetes Mellitus, Type 2 | Diabetes

United States, India, Canada, Spain, Switzerland, Argentina, Finland, Hungary, Russian Federation, Slovenia, Slovakia
Novo Nordisk A/S

Completed

Investigating the Long-term Efficacy and Safety of Two Doses of NN-220 (Somatropin) in Short Stature Due to Noonan Syndrome

Noonan Syndrome | Genetic Disorder

Japan
Novo Nordisk A/S

Completed

Evaluating the Haemostatic Effect of NNC 0129-0000-1003 During Surgical Procedures in Subjects With Haemophilia A. (pathfinder™3)

Congenital Bleeding Disorder | Haemophilia A

France, United States, Denmark, Netherlands, Sweden, Spain, Germany, Switzerland, Taiwan, United Kingdom, Croatia, Malaysia, Brazil, Australia, Hungary, Israel, Turkey, Italy, Japan, Norway, Bulgaria
Novo Nordisk A/S

Withdrawn

A Research Study, Looking at How NovoMix® Works in People With Type 2 Diabetes in Local Clinical Practice in Algeria (B Simple)

Diabetes Mellitus, Type 2

Algeria
Novo Nordisk A/S

Completed

A Trial Comparing Insulin Degludec/Liraglutide and Insulin Degludec in Combination With Metformin in Chinese Subjects With Type 2 Diabetes Mellitus Inadequately Controlled With Basal Insulin Therapy and Metformin With or Without One Other Oral Antidiabetic Drug (OAD) (DUAL™ II China)

Diabetes Mellitus, Type 2 | Diabetes

Hong Kong, China
Novo Nordisk A/S

Completed

A Research Study Looking at How Faster Aspart Injected in Double Concentration Works in the Body of People With Type 1 Diabetes Mellitus

Diabetes Mellitus, Type 1

Germany
Novo Nordisk A/S

Completed

A Trial Investigating the Pharmacokinetic Properties of Insulin Degludec/Insulin Aspart in Healthy Chinese Subjects

Healthy

China
Novo Nordisk A/S

Completed

Safety, Tolerability, and Pharmacokinetics Study of Turoctocog Alfa Pegol Injected Under the Skin in Patients With Haemophilia A (alleviate 1)

Congenital Bleeding Disorder | Haemophilia A

United States, Austria, Serbia, Germany, Japan, France
Novo Nordisk A/S

Completed

Research Study to Investigate How a Study Medicine (NNC9204- 1177) Affects Blood Levels of Other Medicines in Healthy People

Obesity | Overweight | Healthy Volunteers

United States
Novo Nordisk A/S

Completed

RESILIENT: A Research Study, Looking at How Ryzodeg® Works in People With Type 2 Diabetes in Local Clinical Practice in Japan (RESILIENT)

Diabetes Mellitus, Type 2

Japan
Novo Nordisk A/S

Completed

A Study of the Impact of Hemophilia and Its Treatment on Brain Development, Thinking and Behaviour in Children With Hemophilia (eTHINK)

Haemophilia A | Haemophilia B

United States
Novo Nordisk A/S

Completed

An International Non-interventional Cohort Study to Evaluate the Safety of Treatment With Insulin Detemir in Pregnant Women With Diabetes Mellitus. Diabetes Pregnancy Registry

Diabetes Mellitus, Type 2 | Diabetes Mellitus | Diabetes Mellitus, Type 1

Israel, United Kingdom, France, Netherlands, Spain, Finland, Malaysia, Norway, Italy, Germany, Poland, Romania, Portugal, Ireland, Croatia, Greece
Novo Nordisk A/S

Completed

French National Registry of Adults With Growth Hormone Deficiency Treated With Somatropin

Growth Hormone Disorder | Adult Growth Hormone Deficiency

France
Novo Nordisk A/S

Completed

Post-marketing Surveillance (Special Use-results Surveillance) on Long-term Use With Ryzodeg®

Diabetes

Japan
Novo Nordisk A/S

Completed

Efficacy and Safety of Semaglutide Versus Dulaglutide as add-on to Metformin in Subjects With Type 2 Diabetes. (SUSTAIN 7)

Diabetes Mellitus, Type 2 | Diabetes

United States, Croatia, India, Slovakia, Spain, United Kingdom, Finland, Ireland, Germany, Greece, Puerto Rico, Romania, Bulgaria, Latvia, Hong Kong, Lithuania, Portugal
Novo Nordisk A/S

Completed

Research Study Comparing a New Medicine Semaglutide to Liraglutide in People With Type 2 Diabetes (SUSTAIN 10)

Diabetes Mellitus, Type 2 | Diabetes

Italy, Spain, United Kingdom, France, Sweden, Finland, Poland, Slovenia, Hungary, Germany, Bulgaria, Czechia
Novo Nordisk A/S

Completed

Validation of a Questionnaire That Identifies the Reasons for Non-adherence to Existing Growth Hormone Therapy

Growth Hormone Deficiency in Children

Germany
Novo Nordisk A/S

Completed

A Research Study of NNC0165-1875 Alone or Together With Semaglutide in People Who Are Overweight or Obese

Obesity and Overweight

United States
Novo Nordisk A/S

Completed

A Randomised Controlled Clinical Trial in Type 2 Diabetes Comparing Semaglutide to Placebo and Liraglutide

Diabetes Mellitus, Type 2 | Diabetes

India, Italy, Spain, Austria, Finland, Hungary, Turkey, France, United Kingdom, Switzerland, Bulgaria, Germany, South Africa, Former Serbia and Montenegro
University of Nevada, Reno

Completed

Growth Mindset Psychoeducation for Modifiable Risk Factors for CMD

Depression, Anxiety

United States
Novo Nordisk A/S

Completed

Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results (LEADER®)

Diabetes Mellitus, Type 2 | Diabetes

United States, Poland, India, Israel, Italy, Mexico, Puerto Rico, Russian Federation, Spain, United Kingdom, Denmark, Sweden, Netherlands, Austria, Belgium, Taiwan, Finland, Norway, Serbia, South Africa, Turkey, Canada, France, Germany, Korea, Republic of and more
Novo Nordisk A/S

Completed

A Research Study Looking at a New Study Medicine (NNC0194-0499) for Weight Control in People With Overweight or Obesity

Obesity | Metabolism and Nutrition Disorder

United States
Novo Nordisk A/S

Completed

A Research Study of How NNC0174-0833 Behaves in Japanese and Caucasian Volunteers Who Are Normal Weight, Overweight or With Obesity

Obesity | Overweight

United States
Novo Nordisk A/S

Completed

Efficacy and Safety of Semaglutide Once-weekly Versus Sitagliptin Once-daily as add-on to Metformin and/or TZD in Subjects With Type 2 Diabetes (SUSTAIN™ 2)

Diabetes Mellitus, Type 2 | Diabetes

India, Japan, Russian Federation, Spain, Sweden, Argentina, Hungary, Norway, South Africa, Turkey, Bulgaria, Romania, Thailand, Portugal, Hong Kong, Mexico, Ukraine, Czechia
Novo Nordisk A/S

Completed

Efficacy and Safety of FIAsp Compared to Insulin Aspart Both in Combination With Insulin Detemir in Adults With Type 1 Diabetes (onset® 1)

Diabetes | Diabetes Mellitus, Type 1

United States, Poland, Finland, Belgium, Hungary, United Kingdom, Germany, Canada, Czechia
Novo Nordisk A/S

Completed

Efficacy and Safety of FIAsp in a Basal-bolus Regimen Versus Basal Insulin Therapy, Both in Combination With Metformin in Adult Subjects With Type 2 Diabetes (onset® 3)

Diabetes Mellitus, Type 2 | Diabetes

United States, India, Mexico, Argentina, Slovenia, Romania
Novo Nordisk A/S

Completed

Efficacy and Safety of Semaglutide Once-weekly Versus Placebo as add-on to Basal Insulin Alone or Basal Insulin in Combination With Metformin in Subjects With Type 2 Diabetes (SUSTAIN™ 5)

Diabetes Mellitus, Type 2 | Diabetes

United States, Slovakia, Japan, Puerto Rico, Serbia, Germany
Novo Nordisk A/S

Completed

A Trial Investigating the Efficacy and Safety of Insulin Degludec/Insulin Aspart Once Daily Plus Insulin Aspart for the Remaining Meals Versus Insulin Detemir Once or Twice Daily Plus Meal Time Insulin Aspart in Children and Adolescents With Type 1 Diabetes Mellitus

Diabetes | Diabetes Mellitus, Type 1

United States, India, Russian Federation, Belgium, Spain, Israel, Croatia, Serbia, North Macedonia, South Africa, Slovenia, Brazil, Poland, Canada, Czechia
Novo Nordisk A/S

Completed

Comparing Efficacy and Safety of Thrice Daily Versus Twice Daily NovoMix® 30 (Biphasic Insulin Aspart 30) in Subjects With Type 2 Diabetes Inadequately Controlled With Basal Insulin

Diabetes | Type 2 Diabetes Mellitus

Taiwan, Turkey, India, Algeria, Hong Kong, China, Ukraine
Novo Nordisk A/S

Completed

Efficacy and Safety of Faster-acting Insulin Aspart Compared to NovoRapid® Both in Combination With Insulin Degludec in Children and Adolescents With Type 1 Diabetes (onset®7)

Diabetes | Diabetes Mellitus, Type 1

Germany, United States, India, Israel, Italy, Russian Federation, Japan, Finland, Serbia, Turkey, Bulgaria, Estonia, Czechia, Lithuania, Ukraine, Poland, Latvia, Puerto Rico
Novo Nordisk A/S

Completed

Investigation of Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Multiple Doses of Somapacitan in Subjects With Mild and Moderate Degrees of Hepatic Impairment Compared to Subjects With Normal Hepatic Function.

Growth Hormone Disorder | Growth Hormone Deficiency in Children | Adult Growth Hormone Deficiency

Slovakia
Novo Nordisk A/S

Completed

Investigation of the Effect of Upper Gastrointestinal Disease on the Pharmacokinetics of Oral Semaglutide in Subjects With Type 2 Diabetes.

Diabetes Mellitus, Type 2 | Diabetes

Germany
Novo Nordisk A/S

Completed

Comparing Efficacy and Safety of Insulin Degludec/Insulin Aspart and BIAsp 30 in Subjects With Type 2 Diabetes (BOOST)

Diabetes Mellitus, Type 2 | Diabetes

China
Novo Nordisk A/S

Completed

A Research Study of How Faster-acting Insulin Aspart Moves Into, Through, and Out of the Body and How it Works in the Body When Given Through an Insulin Pump to People With Type 1 Diabetes

Diabetes | Diabetes Mellitus, Type 1

Germany
Novo Nordisk A/S

Completed

Efficacy and Safety of FIAsp Compared to Insulin Aspart in Combination With Insulin Glargine and Metformin in Adults With Type 2 Diabetes (onset® 2)

Diabetes Mellitus, Type 2 | Diabetes

United States, Croatia, India, Israel, Russian Federation, Slovakia, Canada, Serbia, United Kingdom, Puerto Rico
Novo Nordisk A/S

Completed

Investigation on Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Doses of a Long-acting GLP-1 Analogue in Healthy Male Subjects and Male Subjects With Type 2 Diabetes

Healthy | Diabetes Mellitus, Type 2 | Diabetes

Germany
Novo Nordisk A/S

Completed

Non-Interventional Study on Safety of Liraglutide in Subjects With Type 2 Diabetes (Lead-Ph)

Diabetes Mellitus, Type 2 | Diabetes

Philippines
Novo Nordisk A/S

Completed

Liraglutide or Insulin in Real Life Usage in Patients With Diabetes Mellitus Type 2

Diabetes Mellitus, Type 2 | Diabetes

Germany
Novo Nordisk A/S

Completed

Efficacy and Safety of Switching From Sitagliptin to Liraglutide in Subjects With Type 2 Diabetes Not Achieving Adequate Glycaemic Control on Sitagliptin and Metformin (LIRA-SWITCH™)

Diabetes Mellitus, Type 2 | Diabetes

United States, Israel, Canada, Hungary, India, Spain, Puerto Rico
Novo Nordisk A/S

Terminated

A Trial Investigating the Efficacy and Safety of Insulin Detemir Versus Insulin NPH in Combination With Metformin and Diet/Exercise in Children and Adolescents With Type 2 Diabetes Insufficiently Controlled on Metformin With or Without Other Oral Antidiabetic Drug(s) With or Without Basal Insulin (iDEAt2)

Diabetes Mellitus, Type 2 | Diabetes

United States, India, Mexico, Israel, Taiwan, Malaysia, Hungary, Turkey, Morocco, Germany, South Africa, Portugal, Lebanon, Italy, Brazil, Croatia, Egypt, Spain, Russian Federation, Greece, Argentina, Korea, Republic of, Poland, Serbia
Novo Nordisk A/S

Terminated

A Trial of NNC0109-0012, an Anti-IL-20 Biologic, in Patients With Active Rheumatoid Arthritis Who Are Inadequate Responders to Anti-TNFa Biologics

Inflammation | Rheumatoid Arthritis

United States, Mexico, France, Italy, Spain, Argentina, Belgium, Brazil, Czechia, Germany, Hungary, Poland, United Kingdom
Novo Nordisk A/S

Completed

First Human Dose Trial Investigating Safety, Tolerability and Pharmacokinetics of NNC0194-0499 in Male Subjects With Overweight or Obesity

Obesity | Metabolism and Nutrition Disorder

United States
Novo Nordisk A/S

Terminated

Effect of Inhaled Pre-prandial Human Insulin on Blood Glucose Control in Type 2 Diabetes

Diabetes Mellitus, Type 2 | Diabetes

United States
Novo Nordisk A/S

Completed

A Non-interventional Study of Ability and Willingness to Pay for BIAsp 30 in a Real World Population With Type 2 Diabetes Mellitus (T2DM)

Diabetes Mellitus, Type 2 | Diabetes

India

3

Subscribe